📊 BHVN Key Takeaways
Is Biohaven Ltd. (BHVN) a Good Investment?
Biohaven is a pre-revenue pharmaceutical company with severe financial deterioration, burning $610.2M in free cash flow annually while generating zero revenue. Despite maintaining adequate cash reserves of $230M, the company's negative profitability ratios, massive operating losses of $745.4M, and lack of commercial traction indicate fundamental operational distress that cannot be sustained without significant capital raises or revenue generation.
Biohaven's fundamentals remain very weak: it is generating no reported revenue while posting a $738.82M net loss and burning more than $609M in operating cash flow. Although losses improved year over year and liquidity is currently adequate with $229.96M of cash and a 3.18x current ratio, the business still lacks evidence of durable operating leverage, self-funded growth, or a sustainable profitability path.
Why Buy Biohaven Ltd. Stock? BHVN Key Strengths
- Strong cash position of $230M provides runway for operations
- Healthy current ratio of 3.18x demonstrates adequate short-term liquidity
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
- Loss per share and net loss improved year over year, indicating some operating progress
- Balance sheet leverage appears low with no reported long-term debt and 0.00x debt-to-equity
- Current liquidity is solid, supported by $229.96M in cash and a 3.18x current ratio
BHVN Stock Risks: Biohaven Ltd. Investment Risks
- Complete absence of revenue generation with no clear commercialization timeline
- Operating cash burn of $609.4M annually will deplete cash reserves in approximately 15 months at current burn rate
- Massive net losses of $738.8M and negative ROE of -1418.8% indicate inability to create shareholder value
- No positive operating metrics or profitability indicators across any measurement
- Dependent on successful drug development and FDA approval with no guaranteed outcomes
- No reported revenue means the business is not yet demonstrating commercial traction or recurring earnings power
- Extremely high cash burn and deeply negative operating income suggest future capital needs if spending remains elevated
- Very small equity base and highly negative ROE/ROA reflect weak financial resilience and poor capital efficiency
Key Metrics to Watch
- Path to revenue generation and commercial product launches
- Monthly cash burn rate and remaining cash runway
- Clinical trial progress and FDA approval timelines
- Capital raise activities and dilution impact on shareholders
- Quarterly revenue emergence and commercialization progress
- Operating cash burn relative to cash balance and equity cushion
Biohaven Ltd. (BHVN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.18x current ratio provides a solid financial cushion.
BHVN Profit Margin, ROE & Profitability Analysis
BHVN vs Healthcare Sector: How Biohaven Ltd. Compares
How Biohaven Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biohaven Ltd. Stock Overvalued? BHVN Valuation Analysis 2026
Based on fundamental analysis, Biohaven Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biohaven Ltd. Balance Sheet: BHVN Debt, Cash & Liquidity
BHVN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biohaven Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.73 indicates the company is currently unprofitable.
BHVN Revenue Growth, EPS Growth & YoY Performance
Biohaven Ltd. Dividends, Buybacks & Capital Allocation
BHVN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biohaven Ltd. (CIK: 0001935979)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BHVN
What is the AI rating for BHVN?
Biohaven Ltd. (BHVN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BHVN's key strengths?
Claude: Strong cash position of $230M provides runway for operations. Healthy current ratio of 3.18x demonstrates adequate short-term liquidity. ChatGPT: Loss per share and net loss improved year over year, indicating some operating progress. Balance sheet leverage appears low with no reported long-term debt and 0.00x debt-to-equity.
What are the risks of investing in BHVN?
Claude: Complete absence of revenue generation with no clear commercialization timeline. Operating cash burn of $609.4M annually will deplete cash reserves in approximately 15 months at current burn rate. ChatGPT: No reported revenue means the business is not yet demonstrating commercial traction or recurring earnings power. Extremely high cash burn and deeply negative operating income suggest future capital needs if spending remains elevated.
What is BHVN's revenue and growth?
Biohaven Ltd. reported revenue of N/A.
Does BHVN pay dividends?
Biohaven Ltd. does not currently pay dividends.
Where can I find BHVN SEC filings?
Official SEC filings for Biohaven Ltd. (CIK: 0001935979) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BHVN's EPS?
Biohaven Ltd. has a diluted EPS of $-6.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BHVN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biohaven Ltd. has a STRONG SELL rating with 89% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BHVN stock overvalued or undervalued?
Valuation metrics for BHVN: ROE of -1,418.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BHVN stock in 2026?
Our dual AI analysis gives Biohaven Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BHVN's free cash flow?
Biohaven Ltd.'s operating cash flow is $-609.4M, with capital expenditures of $715.0K.
How does BHVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -1,418.8% (avg: 15%), current ratio 3.18 (avg: 2).